By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

SillaJen 



  Busan    Korea
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
SillaJen Publishes Clinical Data Demonstrating Safe Administration Of Multiple Intravenous Doses Of Oncolytic Virus In Patients With Metastatic Colorectal Cancer 6/29/2015 6:40:16 AM
SillaJen Presents Data Demonstrating Pexa-Vec Synergy With Angiogenesis Inhibitors: A Collaboration With University of California, San Francisco (UCSF) 4/20/2015 1:27:30 PM
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015 11:02:56 AM
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014 10:41:01 AM
SillaJen To Present At The Biotechnology Industry Organization (BIO) Business Forum 6/20/2014 7:11:26 AM
Global Partners SillaJen, TRANSGENE (ENX:TNG) And TRANSGENE (ENX:TNG) Confirm Clinical Development Plan For Pexa-Vec 3/26/2014 9:53:54 AM
SillaJen Grabs Jennerex, Inc. for $150 Million 11/26/2013 6:53:02 AM
//-->